New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents.


Journal

Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615

Informations de publication

Date de publication:
04 2021
Historique:
received: 18 08 2020
accepted: 04 01 2021
pubmed: 31 1 2021
medline: 4 11 2021
entrez: 30 1 2021
Statut: ppublish

Résumé

2C (2C-x) is the general name for the family of phenethylamines containing two methoxy groups at the 2 and 5 positions of the benzene ring. The abuse of 2C family drugs has grown rapidly, although the abuse potential and neurotoxic properties of 2C drugs have not yet been fully investigated. In this study, we investigated the abuse potential and neurotoxicity of 4-chloro-2,5-dimethoxyphenethylamine (2C-C) and 2,5-dimethoxy-4-propylphenethylamine (2C-P). We found that 2C-C and 2C-P produced conditioned place preference in a dose-dependent manner in mice, and increased self-administration in rats, suggesting that 2C-C and 2C-P have abuse potential. To investigate the neurotoxicity of 2C-C and 2C-P, we examined motor performance and memory impairment after high doses of 2C-C and 2C-P. High doses of 2C-C and 2C-P decreased locomotor activity, rota-rod performance, and lower Y-maze test, novel objective recognition test, and passive avoidance test scores. We also observed that 2C-C and 2C-P affected expression levels of the D1 dopamine receptor, D2 dopamine receptor, dopamine transporter, and phospho-dopamine transporter in the nucleus accumbens and the medial prefrontal cortex, and increased c-Fos immuno-positive cells in the nucleus accumbens. Moreover, high doses of 2C-C and 2C-P induced microglial activation, which is involved in the inflammatory reaction in the striatum. These results suggest that 2C-C and 2C-P have abuse potential by affecting dopaminergic signaling and induce neurotoxicity via initiating neuroinflammation at high doses.

Identifiants

pubmed: 33515270
doi: 10.1007/s00204-021-02980-x
pii: 10.1007/s00204-021-02980-x
doi:

Substances chimiques

2,5-dimethoxy-4-n-propylthiophenethylamine 0
Designer Drugs 0
Phenethylamines 0
Dopamine VTD58H1Z2X

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1413-1429

Commentaires et corrections

Type : ErratumIn

Références

Abou Baker DH, Ibrahim BMM, Hassan NS, Yousuf AF, Gengaihi SE (2020) Exploiting Citrus aurantium seeds and their secondary metabolites in the management of Alzheimer disease. Toxicol Rep 7:723–729. https://doi.org/10.1016/j.toxrep.2020.06.001
doi: 10.1016/j.toxrep.2020.06.001 pubmed: 32551234 pmcid: 7289753
Aloizou AM, Siokas V, Sapouni EM et al (2020) Parkinson’s disease and pesticides: are microRNAs the missing link? Sci Total Environ 744:140591. https://doi.org/10.1016/j.scitotenv.2020.140591
doi: 10.1016/j.scitotenv.2020.140591 pubmed: 32721662
Ares-Santos S, Granado N, Oliva I, O’Shea E, Martin ED, Colado MI, Moratalla R (2012) Dopamine D1 receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis 45(2):810–820. https://doi.org/10.1016/j.nbd.2011.11.005
doi: 10.1016/j.nbd.2011.11.005 pubmed: 22115942
Asanuma M, Miyazaki I, Funada M (2020) The neurotoxicity of psychoactive phenethylamines “2C series” in cultured monoaminergic neuronal cell lines. Forensic Toxicol 38(2):394–408. https://doi.org/10.1007/s11419-020-00527-w
doi: 10.1007/s11419-020-00527-w
Bachiller S, Jimenez-Ferrer I, Paulus A, Yang Y, Swanberg M, Deierborg T, Boza-Serrano A (2018) Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci 12:488. https://doi.org/10.3389/fncel.2018.00488
doi: 10.3389/fncel.2018.00488 pubmed: 30618635 pmcid: 6305407
Bartlett SE, Enquist J, Hopf FW et al (2005) Dopamine responsiveness is regulated by targeted sorting of D2 receptors. ProcNatlAcadSci USA 102(32):11521–11526. https://doi.org/10.1073/pnas.0502418102
doi: 10.1073/pnas.0502418102
Beirami E, Oryan S, SeyedhosseiniTamijani SM, Ahmadiani A, Dargahi L (2018) Intranasal insulin treatment restores cognitive deficits and insulin signaling impairment induced by repeated methamphetamine exposure. J Cell Biochem 119(2):2345–2355. https://doi.org/10.1002/jcb.26398
doi: 10.1002/jcb.26398 pubmed: 28884876
Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8(1):57–69. https://doi.org/10.1038/nrn2038
doi: 10.1038/nrn2038 pubmed: 17180163
Botanas CJ, Yoon SS, de la Pena JB et al (2017) The abuse potential of alpha-Piperidinopropiophenone (PIPP) and alpha-Piperidinopentiothiophenone (PIVT), two new synthetic cathinones with piperidine ring substituent. BiomolTher (Seoul) 25(2):122–129. https://doi.org/10.4062/biomolther.2016.241
doi: 10.4062/biomolther.2016.241
Braren SH, Drapala D, Tulloch IK, Serrano PA (2014) Methamphetamine-induced short-term increase and long-term decrease in spatial working memory affects protein Kinase M zeta (PKMzeta), dopamine, and glutamate receptors. Front BehavNeurosci 8:438. https://doi.org/10.3389/fnbeh.2014.00438
doi: 10.3389/fnbeh.2014.00438
Cervinski MA, Foster JD, Vaughan RA (2005) Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J BiolChem 280(49):40442–40449. https://doi.org/10.1074/jbc.M501969200
doi: 10.1074/jbc.M501969200
Chauhan H, Killinger BA, Miller CV, Moszczynska A (2014) Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum. Int J MolSci 15(4):5884–5906. https://doi.org/10.3390/ijms15045884
doi: 10.3390/ijms15045884
Cole RD, Wolsh C, Zimmerman M, Harrington E, Gould TJ, Parikh V (2019) Adolescent and adult nicotine exposure differentially impacts oral nicotine and oral saccharin self-administration in mice. Behav Brain Res 359:836–844. https://doi.org/10.1016/j.bbr.2018.07.019
doi: 10.1016/j.bbr.2018.07.019 pubmed: 30053462
Cole RL, Konradi C, Douglass J, Hyman SE (1995) Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 14(4):813–823. https://doi.org/10.1016/0896-6273(95)90225-2
doi: 10.1016/0896-6273(95)90225-2 pubmed: 7718243 pmcid: 4207064
Çomaklı S, Sevim Ç, Kontadakis G et al (2019) Acute glufosinate-based herbicide treatment in rats leads to increased ocular interleukin-1β and c-Fos protein levels, as well as intraocular pressure. Toxicol Rep 6:155–160. https://doi.org/10.1016/j.toxrep.2019.01.004
doi: 10.1016/j.toxrep.2019.01.004 pubmed: 30723690 pmcid: 6351388
Cornish JL, Hunt GE, Robins L, McGregor IS (2012) Regional c-Fos and FosB/DeltaFosB expression associated with chronic methamphetamine self-administration and methamphetamine-seeking behavior in rats. Neuroscience 206:100–114. https://doi.org/10.1016/j.neuroscience.2012.01.004
doi: 10.1016/j.neuroscience.2012.01.004 pubmed: 22266344
Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR (2015) Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend 146:30–38. https://doi.org/10.1016/j.drugalcdep.2014.10.027
doi: 10.1016/j.drugalcdep.2014.10.027 pubmed: 25479916
Custodio RJP, Sayson LV, Botanas CJ et al (2019) 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential. Addict Biol. https://doi.org/10.1111/adb.12850
doi: 10.1111/adb.12850 pubmed: 31749223
Dardiotis E, Aloizou AM, Sakalakis E et al (2020) Organochlorine pesticide levels in Greek patients with Parkinson’s disease. Toxicol Rep 7:596–601. https://doi.org/10.1016/j.toxrep.2020.03.011
doi: 10.1016/j.toxrep.2020.03.011 pubmed: 32426240 pmcid: 7225589
Daza-Losada M, Ribeiro Do Couto B, Manzanedo C, Aguilar MA, Rodriguiz-Arias M, Minarro J (2007) Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice. Neuropsychopharmacology 32(8):1750–1759. https://doi.org/10.1038/sj.npp.1301309
doi: 10.1038/sj.npp.1301309 pubmed: 17299518
Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36(1):1–22. https://doi.org/10.1016/s0165-0173(01)00054-6
doi: 10.1016/s0165-0173(01)00054-6 pubmed: 11516769
Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 9(2):172–178. https://doi.org/10.1007/s13181-013-0295-x
doi: 10.1007/s13181-013-0295-x pubmed: 23494844 pmcid: 3657019
Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, Baumann MH (2018) Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 142:240–250. https://doi.org/10.1016/j.neuropharm.2018.02.033
doi: 10.1016/j.neuropharm.2018.02.033 pubmed: 29501528 pmcid: 6119551
Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB (2014) Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology 231(5):875–888. https://doi.org/10.1007/s00213-013-3303-6
doi: 10.1007/s00213-013-3303-6 pubmed: 24142203
FDA (2017) Assessment of abuse potential of drugs guidance for industry. Food and Drug administration, pp 1–37. Retrieved from https://www.fda.gov/media/116739/download
Foster JD, Vaughan RA (2017) Phosphorylation mechanisms in dopamine transporter regulation. J ChemNeuroanat 83–84:10–18. https://doi.org/10.1016/j.jchemneu.2016.10.004
doi: 10.1016/j.jchemneu.2016.10.004
Galaj E, Bi GH, Moore A et al (2020) Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of PPARα and PPARγ: repurposing a FDA-approved food additive for cocaine use disorder. Neuropsychopharmacology. https://doi.org/10.1038/s41386-020-00885-4
doi: 10.1038/s41386-020-00885-4 pubmed: 33069159
Gannon BM, Baumann MH, Walther D et al (2018) The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. Neuropsychopharmacology. https://doi.org/10.1038/s41386-018-0209-3
doi: 10.1038/s41386-018-0209-3 pubmed: 30305739 pmcid: 6180085
Gehrke BJ, Harrod SB, Cass WA, Bardo MT (2003) The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats. Psychopharmacology 166(3):249–257. https://doi.org/10.1007/s00213-002-1318-5
doi: 10.1007/s00213-002-1318-5 pubmed: 12589519
Gilbert DB, Cooper SJ (1985) β-Phenylethylamine and amphetamine compared in tests of anorexia and place-preference conditioning. In: Boulton AA, Maitre L, Bieck PR, Riederer P (eds) Neuropsychopharmacology of the trace amines: experimental and clinical aspects. Humana Press, Totowa, NJ, pp 187–193
doi: 10.1007/978-1-4612-5010-4_17
GovTrack.us (2012) S. 3187 112th Congress: food and drug administration safety and innovation act., 112th edn. Retrieved from https://www.govinfo.gov/content/pkg/BILLS-112s3187enr/pdf/BILLS-112s3187enr.pdf
Hansen DV, Hanson JE, Sheng M (2018) Microglia in Alzheimer’s disease. J Cell Biol 217(2):459–472. https://doi.org/10.1083/jcb.201709069
doi: 10.1083/jcb.201709069 pubmed: 29196460 pmcid: 5800817
Ikemoto S, Wise RA (2002) Rewarding effects of the cholinergic agents carbachol and neostigmine in the posterior ventral tegmental area. J Neurosci 22(22):9895. https://doi.org/10.1523/JNEUROSCI.22-22-09895.2002
doi: 10.1523/JNEUROSCI.22-22-09895.2002 pubmed: 12427846 pmcid: 6757811
Liddelow SA, Guttenplan KA, Clarke LE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487. https://doi.org/10.1038/nature21029
doi: 10.1038/nature21029 pubmed: 28099414 pmcid: 5404890
Luikinga SJ, Perry CJ, Madsen HB, Lawrence AJ, Kim JH (2019) Effects of methamphetamine exposure on fear learning and memory in adult and adolescent rats. Neurochem Res 44(9):2081–2091. https://doi.org/10.1007/s11064-019-02845-x
doi: 10.1007/s11064-019-02845-x pubmed: 31338719
Nagai F, Nonaka R, Satoh HisashiKamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559(2–3):132–137. https://doi.org/10.1016/j.ejphar.2006.11.075
doi: 10.1016/j.ejphar.2006.11.075 pubmed: 17223101
Nestler EJ (2012) Transcriptional mechanisms of drug addiction. ClinPsychopharmacolNeurosci 10(3):136–143. https://doi.org/10.9758/cpn.2012.10.3.136
doi: 10.9758/cpn.2012.10.3.136
Noda Y, Mouri A, Ando Y et al (2010) Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int J Neuropsychopharm 13(10):1343–1354. https://doi.org/10.1017/S1461145710000222
doi: 10.1017/S1461145710000222
Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (2015) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546–553. https://doi.org/10.1016/j.neuropharm.2015.08.034
doi: 10.1016/j.neuropharm.2015.08.034 pubmed: 26318099
Russo SJ, Nestler EJ (2013) The brain reward circuitry in mood disorders. Nat Rev Neurosci 14(9):609–625. https://doi.org/10.1038/nrn3381
doi: 10.1038/nrn3381 pubmed: 23942470
Seo JY, Hur KH, Ko YH et al (2019) A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res Bull 152:19–26. https://doi.org/10.1016/j.brainresbull.2019.07.002
doi: 10.1016/j.brainresbull.2019.07.002 pubmed: 31279579
Shulgin AT, Shulgin A (1990) PiHKAL, The chmical love story. Transform Press, Berkely
Siokas V, Aslanidou P, Aloizou AM et al (2020) Does the CD33 rs3865444 polymorphism confer susceptibility to alzheimer’s disease? J MolNeurosci 70(6):851–860. https://doi.org/10.1007/s12031-020-01507-w
doi: 10.1007/s12031-020-01507-w
Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. ActaNeuropathol 119(1):7–35. https://doi.org/10.1007/s00401-009-0619-8
doi: 10.1007/s00401-009-0619-8
Spanagel R (2017) Animal models of addiction. Dialog ClinNeurosci 19(3):247–258. https://doi.org/10.31887/DCNS.2017.19.3/rspanagel
doi: 10.31887/DCNS.2017.19.3/rspanagel
Stephenson CP, Hunt GE, Topple AN, McGregor IS (1999) The distribution of 3,4-methylenedioxymethamphetamine “Ecstasy”-induced c-fos expression in rat brain. Neuroscience 92(3):1011–1023. https://doi.org/10.1016/S0306-4522(99)00049-4
doi: 10.1016/S0306-4522(99)00049-4 pubmed: 10426541
Stoller A, Dolder PC, Bodmer M et al (2017) Mistaking 2C-P for 2C-B: what a difference a letter makes. J Anal Toxicol 41(1):77–79. https://doi.org/10.1093/jat/bkw108
doi: 10.1093/jat/bkw108 pubmed: 28130544
Teixeira-Gomes A, Costa VM, Feio-Azevedo R, BastosMde L, Carvalho F, Capela JP (2015) The neurotoxicity of amphetamines during the adolescent period. Int J Dev Neurosci 41:44–62. https://doi.org/10.1016/j.ijdevneu.2014.12.001
doi: 10.1016/j.ijdevneu.2014.12.001 pubmed: 25482046
Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J PharmacolExpTher 311(1):1–7. https://doi.org/10.1124/jpet.104.070961
doi: 10.1124/jpet.104.070961
Volkow ND, Fowler JS, Wang GJ (2002) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. BehavPharmacol 13(5–6):355–366. https://doi.org/10.1097/00008877-200209000-00008
doi: 10.1097/00008877-200209000-00008
Volkow ND, Wise RA, Baler R (2017) The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci 18(12):741–752. https://doi.org/10.1038/nrn.2017.130
doi: 10.1038/nrn.2017.130 pubmed: 29142296
Xu W, Zhu JP, Angulo JA (2005) Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse (New York, NY) 58(2):110–121. https://doi.org/10.1002/syn.20185
doi: 10.1002/syn.20185

Auteurs

Young-Jung Kim (YJ)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Shi-Xun Ma (SX)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Kwang-Hyun Hur (KH)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Youyoung Lee (Y)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Yong-Hyun Ko (YH)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Bo-Ram Lee (BR)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Seon-Kyung Kim (SK)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Su-Jeong Sung (SJ)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Kyeong-Man Kim (KM)

Pharmacology Laboratory, College of Pharmacy, Chonnam National University, Gwangju, 81186, Republic of Korea.

Hyoung-Chun Kim (HC)

Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Chuncheon, 24341, Republic of Korea.

Seok-Yong Lee (SY)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.

Choon-Gon Jang (CG)

Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea. jang@skku.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH